Foundry CBOperProf Factor ETF
ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Hypothetical growth of $1 — long-short backtest
Gross of the placeholder expense ratio and trading costs · not investor results
Holdings
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1NVDA | NVIDIA CORP | Technology | $4.91T | 18.98% |
2AAPL | APPLE INC | Technology | $4.90T | 18.96% |
3GOOGL | ALPHABET INC | Communication Services | $4.20T | 16.25% |
4AMZN | AMAZON COM INC | Consumer Cyclical | $2.66T | 10.29% |
5META | META PLATFORMS INC | Communication Services | $1.64T | 6.34% |
6LLY | ELI LILLY & CO | Healthcare | $1.11T | 4.30% |
7MU | MICRON TECHNOLOGY INC | Technology | $958.80B | 3.71% |
8MA | MASTERCARD INC | Financial Services | $480.32B | 1.86% |
9AMAT | APPLIED MATERIALS INC | Technology | $420.53B | 1.63% |
10LRCX | LAM RESEARCH CORP | Technology | $391.80B | 1.52% |
11MRK | MERCK & CO INC | Healthcare | $314.90B | 1.22% |
12KLAC | KLA CORP | Technology | $277.91B | 1.07% |
13SNDK | SANDISK CORP | Technology | $200.63B | 0.78% |
14QCOM | QUALCOMM INC | Technology | $181.06B | 0.70% |
15STX | SEAGATE TECHNOLOGY HOLDINGS PLC | Technology | $176.62B | 0.68% |
16GILD | GILEAD SCIENCES INC | Healthcare | $166.72B | 0.64% |
17WDC | WESTERN DIGITAL CORP | Technology | $164.49B | 0.64% |
18APP | APPLOVIN CORP | Technology | $142.62B | 0.55% |
19SCCO | SOUTHERN COPPER CORP | Basic Materials | $142.48B | 0.55% |
20BKNG | BOOKING HOLDINGS INC | Industrials | $140.78B | 0.54% |
21BMY | BRISTOL MYERS SQUIBB CO | Healthcare | $124.04B | 0.48% |
22VRTX | VERTEX PHARMACEUTICALS INC | Healthcare | $123.26B | 0.48% |
23SBUX | STARBUCKS CORP | Consumer Cyclical | $120.23B | 0.47% |
24ADBE | ADOBE INC | Technology | $94.31B | 0.36% |
25DDOG | DATADOG INC | Technology | $92.08B | 0.36% |
26CDNS | CADENCE DESIGN SYSTEMS INC | Technology | $91.05B | 0.35% |
27HCA | HCA HEALTHCARE INC | Healthcare | $82.34B | 0.32% |
28REGN | REGENERON PHARMACEUTICALS INC | Healthcare | $70.94B | 0.27% |
29CIEN | CIENA CORP | Technology | $53.00B | 0.21% |
30EA | ELECTRONIC ARTS INC | Communication Services | $52.38B | 0.20% |
31ALAB | ASTERA LABS INC | Technology | $52.04B | 0.20% |
32GRMN | GARMIN LTD | Technology | $48.13B | 0.19% |
33ADSK | AUTODESK INC | Technology | $46.07B | 0.18% |
34MSCI | MSCI INC | Financial Services | $45.77B | 0.18% |
35IDXX | IDEXX LABORATORIES INC | Healthcare | $44.76B | 0.17% |
36RVMD | REVOLUTION MEDICINES INC | Healthcare | $39.58B | 0.15% |
37NTRA | NATERA INC | Healthcare | $38.87B | 0.15% |
38RBLX | ROBLOX CORP | Communication Services | $37.02B | 0.14% |
39WDAY | WORKDAY INC | Technology | $35.76B | 0.14% |
40ALNY | ALNYLAM PHARMACEUTICALS INC | Healthcare | $35.71B | 0.14% |
41RDDT | REDDIT INC | Communication Services | $34.88B | 0.13% |
42ONC | BEONE MEDICINES LTD | Healthcare | $34.68B | 0.13% |
43UI | UBIQUITI INC | Technology | $33.04B | 0.13% |
44DXCM | DEXCOM INC | Healthcare | $29.58B | 0.11% |
45FICO | FAIR ISAAC CORP | Technology | $29.15B | 0.11% |
46ILMN | ILLUMINA INC | Healthcare | $28.24B | 0.11% |
47MTD | METTLER TOLEDO INTERNATIONAL INC | Healthcare | $26.47B | 0.10% |
48VRSK | VERISK ANALYTICS INC | Industrials | $26.29B | 0.10% |
49VRSN | VERISIGN INC | Technology | $25.27B | 0.10% |
50MDB | MONGODB INC | Technology | $25.12B | 0.10% |
51TEAM | ATLASSIAN CORP | Technology | $23.67B | 0.09% |
52INCY | INCYTE CORP | Healthcare | $23.42B | 0.09% |
53P | EVERPURE INC | Technology | $23.06B | 0.09% |
54UTHR | UNITED THERAPEUTICS CORP | Healthcare | $22.74B | 0.09% |
55NBIX | NEUROCRINE BIOSCIENCES INC | Healthcare | $17.18B | 0.07% |
56LSCC | LATTICE SEMICONDUCTOR CORP | Technology | $17.16B | 0.07% |
57THC | TENET HEALTHCARE CORP | Healthcare | $16.79B | 0.06% |
58NTNX | NUTANIX INC | Technology | $14.89B | 0.06% |
59DECK | DECKERS OUTDOOR CORP | Consumer Cyclical | $14.79B | 0.06% |
60LOGI | LOGITECH INTERNATIONAL SA | Technology | $14.76B | 0.06% |
61EXEL | EXELIXIS INC | Healthcare | $14.06B | 0.05% |
62PINS | PINTEREST INC | Communication Services | $13.00B | 0.05% |
63GDDY | GODADDY INC | Technology | $12.49B | 0.05% |
64NYT | NEW YORK TIMES CO | Consumer Cyclical | $12.29B | 0.05% |
65HAS | HASBRO INC | Consumer Cyclical | $11.54B | 0.04% |
66HUBS | HUBSPOT INC | Technology | $11.49B | 0.04% |
67PODD | INSULET CORP | Healthcare | $11.36B | 0.04% |
68RMBS | RAMBUS INC | Technology | $10.97B | 0.04% |
69CART | INSTACART (MAPLEBEAR INC) | Consumer Cyclical | $10.77B | 0.04% |
70DPZ | DOMINOS PIZZA INC | Consumer Cyclical | $10.72B | 0.04% |
71ARWR | ARROWHEAD PHARMACEUTICALS INC | Healthcare | $10.47B | 0.04% |
72DOCU | DOCUSIGN INC | Technology | $10.07B | 0.04% |
73CORT | CORCEPT THERAPEUTICS INC | Healthcare | $9.72B | 0.04% |
74MANH | MANHATTAN ASSOCIATES INC | Technology | $9.66B | 0.04% |
75HALO | HALOZYME THERAPEUTICS INC | Healthcare | $9.23B | 0.04% |
76MTCH | MATCH GROUP INC | Communication Services | $9.13B | 0.04% |
77IONS | IONIS PHARMACEUTICALS INC | Healthcare | $8.99B | 0.03% |
78IMVT | IMMUNOVANT INC | Healthcare | $8.27B | 0.03% |
79ETSY | ETSY INC | Consumer Cyclical | $7.98B | 0.03% |
80MIRM | MIRUM PHARMACEUTICALS INC | Healthcare | $7.25B | 0.03% |
81SLAB | SILICON LABORATORIES INC | Technology | $7.17B | 0.03% |
82DBX | DROPBOX INC | Technology | $7.14B | 0.03% |
83CRUS | CIRRUS LOGIC INC | Technology | $6.98B | 0.03% |
84SNDR | SCHNEIDER NATIONAL INC | Industrials | $6.69B | 0.03% |
85MXL | MAXLINEAR INC | Technology | $6.43B | 0.02% |
86APPF | APPFOLIO INC | Technology | $6.36B | 0.02% |
87DUOL | DUOLINGO INC | Technology | $6.24B | 0.02% |
88SEZL | SEZZLE INC | Financial Services | $5.87B | 0.02% |
89QLYS | QUALYS INC | Technology | $5.61B | 0.02% |
90TXG | 10X GENOMICS INC | Healthcare | $5.55B | 0.02% |
91PEGA | PEGASYSTEMS INC | Technology | $5.39B | 0.02% |
92KVYO | KLAVIYO INC | Technology | $5.29B | 0.02% |
93TVTX | TRAVERE THERAPEUTICS INC | Healthcare | $5.27B | 0.02% |
94RELY | REMITLY GLOBAL INC | Technology | $5.08B | 0.02% |
95KNSA | KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | Healthcare | $4.92B | 0.02% |
96ACAD | ACADIA PHARMACEUTICALS INC | Healthcare | $4.38B | 0.02% |
97VKTX | VIKING THERAPEUTICS INC | Healthcare | $4.31B | 0.02% |
98CAKE | CHEESECAKE FACTORY INC | Consumer Cyclical | $4.26B | 0.02% |
99BOX | BOX INC | Technology | $4.22B | 0.02% |
100PI | IMPINJ INC | Technology | $4.21B | 0.02% |
101EXTR | EXTREME NETWORKS INC | Technology | $3.97B | 0.02% |
102DOCS | DOXIMITY INC | Healthcare | $3.94B | 0.02% |
103CLBT | CELLEBRITE DI LTD | Technology | $3.81B | 0.01% |
104ALMS | ALUMIS INC | Healthcare | $3.65B | 0.01% |
105NHC | NATIONAL HEALTHCARE CORP | Healthcare | $3.56B | 0.01% |
106RNG | RINGCENTRAL INC | Technology | $3.46B | 0.01% |
107RCUS | ARCUS BIOSCIENCES INC | Healthcare | $3.44B | 0.01% |
108IDYA | IDEAYA BIOSCIENCES INC | Healthcare | $3.16B | 0.01% |
109CARG | CARGURUS INC | Consumer Cyclical | $3.16B | 0.01% |
110AGYS | AGILYSYS INC | Technology | $3.00B | 0.01% |
111RARE | ULTRAGENYX PHARMACEUTICAL INC | Healthcare | $2.88B | 0.01% |
112ADEA | ADEIA INC | Technology | $2.80B | 0.01% |
113CLDX | CELLDEX THERAPEUTICS INC | Healthcare | $2.77B | 0.01% |
114GPOR | GULFPORT ENERGY CORP | Energy | $2.75B | 0.01% |
115AMBA | AMBARELLA INC | Technology | $2.71B | 0.01% |
116GRND | GRINDR INC | Technology | $2.71B | 0.01% |
117KOD | KODIAK SCIENCES INC | Healthcare | $2.67B | 0.01% |
118ALRM | ALARMCOM HOLDINGS INC | Technology | $2.63B | 0.01% |
119CALX | CALIX INC | Technology | $2.50B | 0.01% |
120CMPR | CIMPRESS PLC | Communication Services | $2.49B | 0.01% |
121NRIX | NURIX THERAPEUTICS INC | Healthcare | $2.40B | 0.01% |
122BCRX | BIOCRYST PHARMACEUTICALS INC | Healthcare | $2.36B | 0.01% |
123BHVN | BIOHAVEN LTD | Healthcare | $2.32B | 0.01% |
124INTA | INTAPP INC | Technology | $2.24B | 0.01% |
125CDNA | CAREDX INC | Healthcare | $2.05B | 0.01% |
126SNDX | SYNDAX PHARMACEUTICALS INC | Healthcare | $2.02B | 0.01% |
127HRMY | HARMONY BIOSCIENCES HOLDINGS INC | Healthcare | $1.96B | 0.01% |
128APPN | APPIAN CORP | Technology | $1.92B | 0.01% |
129VRDN | VIRIDIAN THERAPEUTICS INC | Healthcare | $1.86B | 0.01% |
130SRPT | SAREPTA THERAPEUTICS INC | Healthcare | $1.82B | 0.01% |
131SONO | SONOS INC | Technology | $1.80B | 0.01% |
132IMCR | IMMUNOCORE HOLDINGS PLC | Healthcare | $1.78B | 0.01% |
133ASAN | ASANA INC | Technology | $1.77B | 0.01% |
134DV | DOUBLEVERIFY HOLDINGS INC | Technology | $1.75B | 0.01% |
135ANAB | ANAPTYSBIO INC | Healthcare | $1.69B | 0.01% |
136VIR | VIR BIOTECHNOLOGY INC | Healthcare | $1.59B | 0.01% |
137NTLA | INTELLIA THERAPEUTICS INC | Healthcare | $1.59B | 0.01% |
138MLTX | MOONLAKE IMMUNOTHERAPEUTICS | Healthcare | $1.45B | 0.01% |
139ARLO | ARLO TECHNOLOGIES INC | Basic Materials | $1.45B | 0.01% |
140YELP | YELP INC | Communication Services | $1.44B | 0.01% |
141AIP | ARTERIS INC | Technology | $1.43B | 0.01% |
142WINA | WINMARK CORP | Consumer Cyclical | $1.39B | 0.01% |
143REAL | THEREALREAL INC | Consumer Cyclical | $1.35B | 0.01% |
144NVAX | NOVAVAX INC | Healthcare | $1.35B | 0.01% |
145DMLP | DORCHESTER MINERALS LP | Energy | $1.31B | 0.01% |
146HLIT | HARMONIC INC | Technology | $1.31B | 0.01% |
147XNCR | XENCOR INC | Healthcare | $1.30B | 0.01% |
148NSSC | NAPCO SECURITY TECHNOLOGIES INC | Industrials | $1.29B | 0.00% |
149INBX | INHIBRX BIOSCIENCES INC | Healthcare | $1.28B | 0.00% |
150LQDT | LIQUIDITY SERVICES INC | Consumer Cyclical | $1.23B | 0.00% |
151CBRL | CRACKER BARREL OLD COUNTRY STORE INC | Consumer Cyclical | $1.20B | 0.00% |
152HTLD | HEARTLAND EXPRESS INC | Industrials | $1.19B | 0.00% |
153MGTX | MEIRAGTX HOLDINGS PLC | Healthcare | $1.15B | 0.00% |
154CRTO | CRITEO SA | Communication Services | $1.13B | 0.00% |
155UPWK | UPWORK INC | Industrials | $1.12B | 0.00% |
156EYPT | EYEPOINT INC | Healthcare | $1.12B | 0.00% |
157FBRX | FORTE BIOSCIENCES INC | Healthcare | $1.00B | 0.00% |
158VOR | VOR BIOPHARMA INC | Healthcare | $980M | 0.00% |
159ANNX | ANNEXON INC | Healthcare | $950M | 0.00% |
160EVER | EVERQUOTE INC | Communication Services | $925M | 0.00% |
161TDUP | THREDUP INC | Consumer Cyclical | $852M | 0.00% |
162DSP | VIANT TECHNOLOGY INC | Technology | $754M | 0.00% |
163RIGL | RIGEL PHARMACEUTICALS INC | Healthcare | $750M | 0.00% |
164AURA | AURA BIOSCIENCES INC | Healthcare | $723M | 0.00% |
165CARS | CARSCOM INC | Consumer Cyclical | $670M | 0.00% |
166PHR | PHREESIA INC | Healthcare | $662M | 0.00% |
167MNTN | MNTN INC | Technology | $661M | 0.00% |
168NRDS | NERDWALLET INC | Communication Services | $609M | 0.00% |
169FDMT | 4D MOLECULAR THERAPEUTICS INC | Healthcare | $575M | 0.00% |
170OOMA | OOMA INC | Communication Services | $568M | 0.00% |
171NPCE | NEUROPACE INC | Healthcare | $548M | 0.00% |
172YEXT | YEXT INC | Technology | $535M | 0.00% |
173ARVN | ARVINAS INC | Healthcare | $517M | 0.00% |
174RGNX | REGENXBIO INC | Healthcare | $511M | 0.00% |
175NVCT | NUVECTIS PHARMA INC | Healthcare | $508M | 0.00% |
176DCTH | DELCATH SYSTEMS INC | Healthcare | $442M | 0.00% |
177PBYI | PUMA BIOTECHNOLOGY INC | Healthcare | $434M | 0.00% |
178RLGT | RADIANT LOGISTICS INC | Industrials | $431M | 0.00% |
179SGU | STAR GROUP LP | Energy | $430M | 0.00% |
180CBIO | CRESCENT BIOPHARMA INC | Healthcare | $407M | 0.00% |
181ENTA | ENANTA PHARMACEUTICALS INC | Healthcare | $400M | 0.00% |
182NATH | NATHANS FAMOUS INC | Consumer Cyclical | $393M | 0.00% |
183STRO | SUTRO BIOPHARMA INC | Healthcare | $391M | 0.00% |
184CRNC | CERENCE INC | Technology | $390M | 0.00% |
185UPB | UPSTREAM BIO INC | Healthcare | $382M | 0.00% |
186NATR | NATURES SUNSHINE PRODUCTS INC | Consumer Defensive | $359M | 0.00% |
187PLAY | DAVE & BUSTER'S ENTERTAINMENT INC | Communication Services | $355M | 0.00% |
188XPER | XPERI INC | Technology | $352M | 0.00% |
189CV | CAPSOVISION INC | Healthcare | $335M | 0.00% |
190BKKT | BAKKT INC | Technology | $323M | 0.00% |
191MKTW | MARKETWISE INC | Technology | $314M | 0.00% |
192FHTX | FOGHORN THERAPEUTICS INC | Healthcare | $305M | 0.00% |
193QTTB | Q32 BIO INC | Healthcare | $255M | 0.00% |
194ARTV | ARTIVA BIOTHERAPEUTICS INC | Healthcare | $241M | 0.00% |
195GLSI | GREENWICH LIFESCIENCES INC | Healthcare | $240M | 0.00% |
196SPOK | SPOK HOLDINGS INC | Healthcare | $222M | 0.00% |
197KPTI | KARYOPHARM THERAPEUTICS INC | Healthcare | $216M | 0.00% |
198AGEN | AGENUS INC | Healthcare | $209M | 0.00% |
199DTIL | PRECISION BIOSCIENCES INC | Healthcare | $203M | 0.00% |
200EGAN | EGAIN CORP | Technology | $180M | 0.00% |
201ARCT | ARCTURUS THERAPEUTICS HOLDINGS INC | Healthcare | $172M | 0.00% |
202CRBP | CORBUS PHARMACEUTICALS HOLDINGS INC | Healthcare | $167M | 0.00% |
203PMN | PROMIS NEUROSCIENCES INC | Healthcare | $136M | 0.00% |
204VTVT | VTV THERAPEUTICS INC | Healthcare | $130M | 0.00% |
205AARD | AARDVARK THERAPEUTICS INC | Healthcare | $128M | 0.00% |
206CUE | CUE BIOPHARMA INC | Healthcare | $126M | 0.00% |
207INSG | INSEEGO CORP | Technology | $122M | 0.00% |
208SOTK | SONO TEK CORP | Technology | $86M | 0.00% |
209CSBR | CHAMPIONS ONCOLOGY INC | Healthcare | $85M | 0.00% |
210ACET | ADICET BIO INC | Healthcare | $76M | 0.00% |
211ATRA | ATARA BIOTHERAPEUTICS INC | Healthcare | $76M | 0.00% |
212BODI | BEACHBODY COMPANY INC | Communication Services | $75M | 0.00% |
213BGSF | BGSF INC | Industrials | $65M | 0.00% |
214XLO | XILIO THERAPEUTICS INC | Healthcare | $53M | 0.00% |
Full long-leg book as of July 2026 · cap-weighted · total market cap $25.85T. Hypothetical model holdings — not a registered fund’s portfolio.
Sector Breakdown
Portfolio Style
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 3,283-name universe at July 2026. Rows: Large ≥ $5.2B, Small < $819M. Columns: Value ≥ 0.62, Growth < 0.34 B/M. The dot marks the capital-weighted centroid of the book — 100% toward Large, 85% toward Growth. Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → July 2026; the right-hand end is the same value as the box’s dot. 214 names now. Hypothetical holdings — descriptive, not P&L.
Constraint checks
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
2 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.
Required>= 75.0%Actual54.2%Margin-20.8%The fund will not concentrate: no more than 25% of total assets in any one industry (excluding government securities and cash items).
Required<= 25.0%Actual28.4%Margin-3.4%
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
No verdict sits within 1.0pp of its limit.
Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700
Measured on the 2026-07 formation date across 214 holdings (cap-weighted). A different formation date can produce different verdicts.
Derivatives risk (Rule 18f-4)
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months
The estimators agree, which is mild evidence the number isn’t an artefact of one method.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Since publication
Did the edge survive the paper coming out?
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Consistency across eras
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Returns
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 28.6% | 19.8% |
| 3 yearsp.a. | 27.7% | 21.3% |
| 5 yearsp.a. | 18.4% | 26.2% |
| 10 yearsp.a. | 21.8% | 18.8% |
| Since inceptionp.a. | 14.1% | 13.2% |
| Year | Long leg | Long-short |
|---|---|---|
| 20267 mo | 10.4% | 5.1% |
| 2025 | 25.1% | 8.2% |
| 2024 | 42.0% | 36.5% |
| 2023 | 57.2% | 28.8% |
| 2022 | -31.5% | 23.9% |
| 2021 | 30.5% | 42.0% |
| 2020 | 42.0% | -4.0% |
| 2019 | 32.6% | 2.0% |
| 2018 | 2.4% | 24.3% |
| 2017 | 34.2% | 28.6% |
| 2016 | 5.3% | 4.1% |
| 2015 | 9.9% | 17.8% |
| 2014 | 17.8% | 17.6% |
| 2013 | 43.8% | 9.5% |
| 2012 | 15.7% | -3.9% |
| 2011 | 2.6% | 11.7% |
| 2010 | 10.3% | -12.7% |
| 2009 | 37.0% | -15.3% |
| 2008 | -27.9% | 54.5% |
| 2007 | 11.4% | 1.8% |
| 2006 | 11.1% | 0.2% |
| 2005 | 6.9% | 2.5% |
| 2004 | 4.4% | -14.0% |
| 2003 | 22.0% | -19.0% |
| 2002 | -20.2% | 38.7% |
| 2001 | -13.4% | 31.4% |
| 2000 | 16.6% | 136.8% |
| 1999 | 54.4% | -9.5% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
Fund Facts
Methodology
The Foundry CBOperProf Factor ETF tracks a rules-based model that ranks liquid U.S. common stocks (price > $5, market-cap floor) each month by a CBOperProf signal and holds the top decile with the highest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Documents (draft — hypothetical)
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.